🔬 Discover the latest advancements in #BreastCancer research on our Journal Highlights page! Explore top articles on HER2-positive metastatic breast cancer, triple-negative breast cancer, CDK4/6 inhibitors, and more. #OncologyResearch

Explore more: journals.sagepub.com/topic/collecti…

🔬 New phase III trial TROPION-Breast03 evaluates the efficacy of datopotamab deruxtecan (Dato-DXd) ± durvalumab in treating TNBC patients with residual invasive disease post-surgery. Led by Associate Editor Aditya Bardia, MD. Learn more: journals.sagepub.com/doi/full/10.11…

#BreastCancer

📝 Calling researchers! In honor of #BladderCancerAwareness Month, Therapeutic Advances in Medical Oncology is offering a discount for submissions focused on bladder cancer research. Contact us for details: [email protected] or [email protected]

Single arm phase II study of covalent #KRAS G12C inhibitor glecirasib (JAB-21822) in pts with NSCLC presented by Dr. Yuankai Shi at April #ASCOPlenarySeries . Glecirasib 800mg qday in 199pts had confirmed RR 47.9% and disease control rate of 86.3%

Now 4 out of 10 ✅

Dr. Nancy Lin (Nancy Lin, MD) discussed advances in medical treatment in today's #ESMObreast24 educational session on the management of #BrainMetastases from early detection to local and systemic treatments.
#BreastCancerBrainMetastasis #BCBM #LMD
cattendee.abstractsonline.com/meeting/20743/…

A momentous announcement from ASCO ASCOPres-Elect #EricSmall — the newly established Conquer Cancer, the ASCO Foundation Felix Feng Young Investigator Award. Standing ovation in the room.

Donate to the new #FelixFengYIA here:
p2p.conquer.org/uniteandconque…

Great recap of the randomized trials in the 2L+ HR+ MBC setting by Eva M Ciruelos. #ESMOBreast24 #ESMOAmbassadors ESMO - Eur. Oncology

Genes that should be included in germline testing panels by tumor type (including prostate cancer): ASCO guideline just published.

ascopubs.org/doi/pdf/10.120…

Neoadjuvant chemo/nivo with adjuvant nivo show ⬆️ DFS (HR 0.58) & ⬆️pCR in NSCLC. 23% & 35% didn’t have surgery/adjuvant nivo respectively. Debate about activity of neoadjuvant vs adjuvant vs both is ongoing. No OS. Similar Bladder cancer trials (durva/nivo/pembro) awaited.